Calzada, pSivida, GI Dynamics announce board moves

Three ASX-listed biotech companies have proclaimed changes to the make-up of their respective boards of directors.

Calzada (ASX:CZD) has announced the resignation of non-executive director and former chairman Dr Roger Aston.

Calzada appointed Aston to the board as chairman in November last year, but Aston stepped down from the role in March - while retaining a seat on the board - citing increased time commitments from his other executive roles.

Now Aston has left the company altogether, telling the board that his recent appointment as chairman of Oncosil Medical (ASX:OSL) has left him without enough time to adequately serve as a director.

GI Dynamics (ASX:GID) has meanwhile added Daniel Moore to its board as an independent director.

Moore is currently CEO of Cyberonics, a US-based medical device company specialising in vagus nerve stimulation (VNS). He has been in this role since 2007, following 17 years at Boston Scientific.

The appointment brings the size of the GI Dynamics board up to seven, six of whom are non-executive directors.

Finally, pSivida (ASX:PVA) has selected Dr James Barry to join its own board. Barry is currently COO of cardiovascular medical device company Inspire-MD.

Barry has also held roles at companies including Boston Scientific and Arsenal Medial. He currently serves on advisory boards including the College of Biomedical Engineering at Yale University and the College of Sciences at the University of Massachusetts.

Calzada (ASX:CZD) shares were trading unchanged at $0.096 as of around 1.30 pm on Thursday, while pSivida (ASX:PVA) shares were down 0.4% at $5.02 and GI Dynamics (ASX:GID) shares were up 1.96% to $0.52.